Add-on treatment with verapamil in pharmacoresistant canine epilepsy

Epilepsia

Volumn 52, Issue 2, 2011, Pages 284-291

  Jambroszyk, Melanie ^a   Tipold, Andrea ^a   Potschka, Heidrun ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Blood brain barrier; Drug refractoriness; Efflux transporter; Multidrug transporter; P glycoprotein; Pharmacoresistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GLUCOSE; GLUTAMATE DEHYDROGENASE; HEMOGLOBIN; PHENOBARBITAL; PROTEIN; VERAPAMIL;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BRADYCARDIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EPILEPSY; ERYTHROCYTE COUNT; EXPERIMENTAL DOG; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEIZURE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; TREATMENT RESPONSE;

AGE OF ONSET; ANIMALS; ANTICONVULSANTS; BLOOD PRESSURE; BRADYCARDIA; CALCIUM CHANNEL BLOCKERS; DOG DISEASES; DOGS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; MALE; P-GLYCOPROTEIN; PHENOBARBITAL; RECURRENCE; TREATMENT FAILURE; VERAPAMIL;

EID: 79951658672     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02886.x     Document Type: Article

References (26)

1. Bahls FH, Ozuna J, Ritchie DE,. (1991) Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 41: 740-742.
2. Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H,. (2008) Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 73: 1444-1453. (Pubitemid 351574834)
3. Brandt C, Bethmann K, Gastens AM, Loscher W,. (2006) The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24: 202-211. (Pubitemid 44416217)
4. Fox E, Bates SE,. (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7: 447-459. (Pubitemid 46681800)
5. Iannetti P, Spalice A, Parisi P,. (2005) Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46: 967-969. (Pubitemid 40847369)
6. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F,. (2009) Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res 85: 89-95.
7. Loscher W,. (1997) Animal models of intractable epilepsy. Prog Neurobiol 53: 239-258. (Pubitemid 27436002)
8. Loscher W, Potschka H,. (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602. (Pubitemid 41059334)
9. Loscher W, Potschka H, Rieck S, Tipold A, Rundfeldt C,. (2004) Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia 45: 1228-1239. (Pubitemid 39350335)
10. Macphee GJ, McInnes GT, Thompson GG, Brodie MJ,. (1986) Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1: 700-703. (Pubitemid 16143117)
11. Pakozdy A, Leschnik M, Tichy AG, Thalhammer JG,. (2008) Retrospective clinical comparison of idiopathic versus symptomatic epilepsy in 240 dogs with seizures. Acta Vet Hung 56: 471-483.
12. Pekcec A, Unkruer B, Schlichtiger J, Soerensen J, Hartz AM, Bauer B, van Vliet EA, Gorter JA, Potschka H,. (2009a) Targeting prostaglandin E2 EP1 receptors prevents seizure-associated p-glycoprotein up-regulation. J Pharmacol Exp Ther 330: 939-947.
13. Pekcec A, Unkruer B, Stein V, Bankstahl JP, Soerensen J, Tipold A, Baumgartner W, Potschka H,. (2009b) Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res 83: 144-151.
14. Podell M,. (1996) Seizures in dogs. Vet Clin North Am Small Anim Pract 26: 779-809. (Pubitemid 26233986)
15. Porrello A, Cardelli P, Spugnini EP,. (2006) Oncology of companion animals as a model for humans. an overview of tumor histotypes. J Exp Clin Cancer Res 25: 97-105.
16. Potschka H, Fedrowitz M, Loscher W,. (2002) P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 327: 173-176. (Pubitemid 34756625)
17. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A,. (2002) Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 22: 5833-5839.
18. Schlichtiger J, Pekcec A, Bartmann H, Winter P, Fuest C, Soerensen J, Potschka H,. (2010) Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol 160: 1062-1071.
19. Summers MA, Moore JL, McAuley JW,. (2004) Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38: 1631-1634. (Pubitemid 39297759)
20. Thomas W,. (2000) Idiopathic epilepsy in dogs. Vet Clin North Am Small Anim Pract 20: 186-206.
21. Thomas WB,. (2010) Idiopathic epilepsy in dogs and cats. Vet Clin North Am Small Anim Pract 40: 161-179.
22. Thomas H, Coley HM,. (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165. (Pubitemid 36437822)
23. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA,. (2006) Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47: 672-680.
24. van Vliet EA, van Schaik R, Edelbroek PM, Voskuyl RA, Redeker S, Aronica E, Wadman WJ, Gorter JA,. (2007) Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 322: 141-147. (Pubitemid 46956371)
25. Waxman DJ, Azaroff L,. (1992) Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 281 (Pt 3): 577-592.
26. Zibell G, Unkruer B, Pekcec A, Hartz AM, Bauer B, Miller DS, Potschka H,. (2009) Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 56: 849-855.